Metformin and Gabapentin Interaction: What You Need to Know

Is there a direct interaction between metformin and gabapentin?

Metformin's label carries a full table of clinically significant drug interactions. It names carbonic anhydrase inhibitors such as topiramate, drugs that reduce metformin clearance through the organic cation transporter 2 (OCT2) and MATE transporters (ranolazine, vandetanib, dolutegravir and cimetidine), alcohol, insulin and insulin secretagogues, and a group of drugs that can raise blood glucose and cause loss of control [1]. Gabapentin does not appear in that table.

Neither drug depends on the liver for clearance. Metformin is not metabolized, is negligibly bound to plasma proteins and is cleared by the kidneys [1]. Gabapentin is not metabolized by, and does not inhibit, the hepatic enzymes that handle other drugs, and it is excreted renally [2].

Why kidney function matters more than the drug pair

Metformin is excreted unchanged in urine by tubular secretion. Its renal clearance is about 3.5 times creatinine clearance, and its plasma half-life is about 6.2 hours [1]. The label's kidney rules are specific:

• Check eGFR before starting and at least yearly thereafter [1].
• Metformin is contraindicated at an eGFR below 30 mL/min/1.73 m² [1].
• Starting is not recommended at an eGFR of 30 to 45 mL/min/1.73 m² [1].
• If eGFR later falls below 45, the label says to reassess the benefit and risk of continuing, and to stop if it falls below 30 [1].
• The label says kidney function should be assessed more often in older adults and in people at risk of renal impairment [1].

Gabapentin is also cleared by the kidneys, with an elimination half-life of roughly 6 hours [2]. The gabapentin label sets the total daily dose by creatinine clearance: 900 to 3,600 mg a day at 60 mL/min or above, 400 to 1,400 mg a day at above 30 to 59, 200 to 700 mg a day at above 15 to 29, and 100 to 300 mg a day at 15 mL/min, with a proportionally reduced dose below that. For patients on hemodialysis, the label gives a supplemental dose after each 4 hours of hemodialysis, and it says older adults should have doses chosen by creatinine clearance.

One lab value therefore feeds two decisions. A falling eGFR is where the metformin label asks for a benefit-risk review and the gabapentin label calls for a lower daily dose.

HealthRX.com offers metformin by prescription.

Does gabapentin add to metformin's lactic acidosis warning?

Metformin's boxed warning covers lactic acidosis. Postmarketing cases have caused death, hypothermia, hypotension and resistant bradyarrhythmias, and the onset is often subtle, with malaise, muscle aches, breathing difficulty, unusual sleepiness and abdominal pain [1]. Confirmed cases show blood lactate above 5 mmol/L, an anion gap acidosis and metformin levels generally above 5 mcg/mL [1]. The label lists renal impairment, certain interacting drugs, age 65 or older, contrast studies, surgery and other procedures, hypoxic states such as acute heart failure, excessive alcohol intake and hepatic impairment as risk factors, and says cases have primarily occurred in patients with significant renal impairment [1]. Gabapentin is not among the drugs or conditions named [1].

How often this happens is hard to pin down. A systematic review of 65 studies put the incidence of lactic acidosis in metformin users at roughly 3 to 10 per 100,000 person-years, generally indistinguishable from the background rate in people with diabetes, and found no randomized trial testing metformin in significantly impaired kidney function [4].

For suspected metformin-associated lactic acidosis, the label calls for immediate discontinuation and supportive measures in a hospital, and recommends prompt hemodialysis [1].

Sedation and breathing risk belongs to gabapentin plus CNS depressants

This is the gabapentin safety issue that gets confused with a metformin interaction. In December 2019 the FDA warned that serious breathing difficulties can occur with gabapentin and pregabalin in people with respiratory risk factors: opioid pain medicines or other CNS depressants, lung conditions such as COPD, and older age [3]. The agency required new respiratory depression warnings in the labels and advised prescribers to start at the lowest dose and monitor for sedation and breathing problems when a gabapentinoid is combined with an opioid or a benzodiazepine [3]. Symptoms the FDA lists include confusion, unusual dizziness, extreme sleepiness, slowed or shallow breathing, unresponsiveness, and bluish skin on the lips, fingers or toes [3].

The scale of the opioid concern comes from an Ontario nested case-control study: 1,256 opioid-related deaths matched to 4,619 controls, with gabapentin prescribed in the prior 120 days in 12.3% of cases versus 6.8% of controls, an adjusted odds ratio of 1.49 (95% CI 1.18 to 1.88) for opioid-related death [5]. That is observational data about opioids and gabapentin, not about metformin.

Alcohol, contrast dye and sick days

The metformin label says alcohol potentiates the drug's effect on lactate metabolism and warns against excessive intake [1].

Iodinated contrast is a metformin-specific issue. The label says metformin is stopped at the time of or before an iodinated contrast procedure in patients with an eGFR between 30 and 60, in patients with a history of hepatic impairment, alcoholism or heart failure, or when contrast is given intra-arterially; eGFR is re-evaluated 48 hours afterward, and metformin is restarted if renal function is stable [1]. The label also names restricted food and fluid intake, and hypoxic events such as acute heart failure, myocardial infarction and sepsis, as situations in which metformin is temporarily discontinued or stopped [1].

What to watch for

For metformin, the label describes malaise, muscle aches, breathing difficulty, unusual sleepiness and abdominal pain as the possible subtle symptoms of lactic acidosis [1]. For gabapentin, the FDA's symptom list covers confusion, unusual dizziness, extreme sleepiness, slowed or shallow breathing, unresponsiveness and bluish skin, especially in people taking opioids or other CNS depressants [3].